Nutriband Files Provisional Patent Application for Enhanced Transdermal Abuse Deterrent Technology

Core Viewpoint - Nutriband Inc. has filed a provisional patent application to enhance its AVERSA™ transdermal abuse deterrent technology aimed at preventing the misuse of opioids and stimulants [1][2]. Group 1: Patent Application and Technology - The provisional patent application focuses on improved aversive formulations and coating methods to strengthen the abuse deterrent properties of the AVERSA™ technology [2]. - If converted to a non-provisional patent, it could extend patent protection for products utilizing AVERSA™ for 20 years from the non-provisional filing date [2]. - The AVERSA™ technology is protected by a broad international intellectual property portfolio with patents issued in 46 countries, including the U.S., Europe, Japan, and China [3]. Group 2: Technology Applications and Benefits - AVERSA™ technology incorporates aversive agents into transdermal patches to prevent abuse, diversion, misuse, and accidental exposure of drugs with abuse potential, such as opioids and stimulants [4][5]. - This technology aims to improve the safety profile of transdermal drugs while ensuring accessibility for patients who genuinely need them [4][5]. Group 3: Company Overview - Nutriband Inc. is primarily focused on developing a portfolio of transdermal pharmaceutical products, with its lead product being an abuse-deterrent fentanyl patch utilizing AVERSA™ technology [6].